Bajaj Healthcare Ltd (BAJAJHCARE) AI Stock Analysis

• Market Cap: ₹14.41B
• Dividend Yield: 0.22%
• Average Volume (3M): 30.17K
• Price to Earnings (P/E): 31.0
• Beta (1Y): 0.74
• Revenue Growth: 13.04%
• EPS Growth: N/A
• Country: IN
• Employees: 1,049
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 3.52
• Shares Outstanding: 31,583,252
• 10 Day Avg. Volume: 8,197
• 30 Day Avg. Volume: 30,174
• PEG Ratio: -0.38
• Price to Book (P/B): 4.64
• Price to Sales (P/S): 3.98
• P/FCF Ratio: -124.79
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 54 Neutral
• Price Target: ₹469.00 ▼(-0.32% Downside)

Bajaj Healthcare Ltd's stock score is primarily influenced by its moderate financial performance, characterized by profitability challenges and high leverage. Technical analysis indicates mixed signals with limited momentum, while valuation metrics suggest the stock is relatively expensive. The absence of earnings call data and corporate events limits additional insights.

Bajaj Healthcare Ltd Business Overview & Revenue Model

Company Description

Bajaj HealthCare Limited, a pharmaceutical company, develops, manufactures, and supplies amino acids, nutritional supplements, and active pharmaceutical ingredients (APIs) for pharmaceutical, nutraceuticals, and food industries in India and internationally. The company's product portfolio consists of various APIs in the therapeutic categories of anti-diabetic, antibiotic, antiviral, antiplatelet, antifungal, antihelmintic, iron-chelating agent, anticonvulsant, growth stimulant, non-steroidal anti-inflammatory drugs, antihypertensive, anthelmintics, anti-asthmatic, antioxidant, urinary tract infection, anti-histamine, weight reducing, venous disease, antimalarial, vitamin c, disinfectant/ antiseptic, stimulant, anticonvulsant, lipotropic agents, nootropic, vasoprotective/ antihemorrhagic, cardiovascular agent, food supplements, anti-anemic, amino acids, antiasthmatic / bronchodilator, nutritional supplement, and minerals. It also provides formulations in the form of tablets, capsules, and powder, as well as impurities. In addition, the company exports its products. Bajaj HealthCare Limited was incorporated in 1993 and is based in Thane, India.

How the Company Makes Money

Bajaj Healthcare generates revenue primarily through the sale of its pharmaceutical products, including APIs and finished formulations, to various clients, including pharmaceutical companies and distributors. The company has established key partnerships with domestic and international pharmaceutical firms, which contribute significantly to its revenue streams. Additionally, Bajaj Healthcare benefits from contract manufacturing agreements that allow it to produce products for other companies, further diversifying its income sources. The company also invests in research and development to innovate new products and expand its market reach, which plays a crucial role in driving its earnings.

Bajaj Healthcare Ltd Financial Statement Overview

Summary

Bajaj Healthcare Ltd shows moderate profitability with significant leverage and cash flow management challenges. The income statement reflects some recovery in net income, but high leverage and inconsistent cash flow pose financial risks.

Income Statement

The company's revenue has shown fluctuating growth over recent years, with a decline in 2025 compared to 2023. Gross profit margin and EBIT margin have decreased, indicating potential cost management issues. However, the net profit margin improved in 2025, recovering from negative profitability in 2024. Overall, the income statement reflects moderate profitability with some volatility in revenue growth.

Balance Sheet

The debt-to-equity ratio is relatively high, indicating significant leverage which could pose financial risks. Return on equity has been inconsistent, reflecting variability in net income. The equity ratio has improved, indicating a healthier balance between debt and assets, but the overall leverage remains a concern.

Cash Flow

Cash flow from operations has been inconsistent, with negative free cash flow in recent years. The operating cash flow to net income ratio is concerning, indicating challenges in converting profits into cash. Financing cash flows have been positive, suggesting reliance on external financing. Overall, cash flow management presents a potential area of concern.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	5.59B	5.43B	4.73B	6.46B	6.79B	6.56B
Gross Profit	2.35B	1.71B	2.14B	1.33B	1.84B	1.93B
EBITDA	1.02B	1.02B	406.24M	1.22B	1.20B	1.43B
Net Income	441.97M	394.95M	-837.93M	430.24M	713.86M	831.09M
Balance Sheet
Total Assets	0.00	8.33B	7.65B	9.01B	7.21B	5.26B
Cash, Cash Equivalents and Short-Term Investments	44.51M	44.51M	29.29M	192.29M	19.75M	142.41M
Total Debt	0.00	2.23B	3.33B	4.15B	2.57B	1.81B
Total Liabilities	-4.66B	3.67B	4.87B	5.34B	3.93B	2.67B
Stockholders Equity	4.66B	4.66B	2.78B	3.68B	3.28B	2.58B
Cash Flow
Free Cash Flow	0.00	-173.16M	620.08M	-1.46B	-786.19M	-702.30M
Operating Cash Flow	0.00	-57.78M	922.94M	-223.24M	6.86M	435.58M
Investing Cash Flow	0.00	-153.21M	-112.45M	-934.27M	-747.98M	-1.09B
Financing Cash Flow	0.00	215.28M	-965.96M	1.31B	618.46M	754.57M

Bajaj Healthcare Ltd Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 470.50
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:BAJAJHCARE, the sentiment is Negative. The current price of 470.5 is below the 20-day moving average (MA) of 474.31, above the 50-day MA of 450.98, and below the 200-day MA of 542.57, indicating a bearish trend. The MACD of 0.88 indicates Positive momentum. The RSI at 44.15 is Neutral, neither overbought nor oversold. The STOCH value of 13.63 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:BAJAJHCARE.

Bajaj Healthcare Ltd Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BLISSGVS	69 Neutral	₹16.49B	15.33	―	0.33%	4.93%	29.92%
JAGSNPHARM	67 Neutral	₹14.80B	23.91	―	1.16%	34.72%	196.94%
SYNCOMF	65 Neutral	₹15.38B	26.72	―	―	70.43%	101.61%
THEMISMED	63 Neutral	₹11.63B	―	―	0.39%	-6.86%	-118.14%
HESTERBIO	61 Neutral	₹14.73B	38.76	―	0.42%	4.68%	94.22%
BAJAJHCARE	54 Neutral	₹14.41B	30.97	―	0.22%	13.04%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Bajaj Healthcare Ltd Corporate Events

Bajaj Healthcare Publishes Un-Audited Financial Results for September 2025

Bajaj Healthcare Limited has announced the publication of its un-audited financial results for the quarter and half-year ending September 30, 2025, in compliance with SEBI regulations. The results were published in the Financial Express and Mumbai Lakshadweep newspapers, reflecting the company’s commitment to transparency and regulatory adherence, potentially impacting its market perception and stakeholder confidence.

Bajaj Healthcare Announces 32nd AGM and Annual Report Dispatch

Bajaj Healthcare Limited has announced the dispatch of the notice for its 32nd Annual General Meeting (AGM) and the Annual Report for the fiscal year 2024-25. The company has provided e-voting facilities for its members to participate in the AGM, which will be held through video conferencing. This move ensures compliance with SEBI regulations and enhances shareholder engagement by facilitating remote participation. The announcement underscores Bajaj Healthcare’s commitment to transparency and regulatory adherence, potentially strengthening its position in the healthcare sector.

Bajaj Healthcare Ltd Announces Virtual AGM for 2025

Bajaj Healthcare Ltd has announced its 32nd Annual General Meeting (AGM) scheduled for September 26, 2025, to be conducted via video conferencing. The company has dispatched notices to shareholders, providing access to the annual report for the fiscal year 2024-25. This AGM will allow shareholders to engage in e-voting, ensuring participation in the company’s decision-making process. The announcement highlights the company’s ongoing commitment to transparency and stakeholder engagement, reinforcing its position in the pharmaceutical sector.

Bajaj Healthcare Launches ‘Saksham Niveshak’ Campaign to Engage Shareholders

Bajaj Healthcare Limited has launched a 100-day campaign called ‘Saksham Niveshak’ to encourage its shareholders to claim unpaid or unclaimed dividends or shares. This initiative aligns with a circular from the Investor Education and Protection Fund Authority, aiming to prevent these funds from being transferred to the Investor Education and Protection Fund. The company has published advertisements in newspapers to raise awareness among shareholders, which could enhance shareholder engagement and potentially improve the company’s financial management.

Bajaj Healthcare Releases Q1 2025 Financial Results

Bajaj Healthcare Limited has published its un-audited financial results for the quarter ending June 30, 2025, in compliance with SEBI regulations. The results, which were released in major newspapers, indicate the company’s ongoing financial performance and are part of its regulatory disclosure obligations, potentially impacting stakeholders’ insights into its operational health.

Bajaj Healthcare Reports Strong Q1 FY26 Results with Significant Profit Growth

Bajaj Healthcare Limited reported a strong performance for the first quarter of FY26, with a 12.5% increase in revenue to ₹1,488.4 million and a significant 66% growth in profit after tax to ₹118.3 million. The company achieved this despite challenging pricing conditions, by improving its product mix and leveraging operating efficiencies. The API export segment experienced a remarkable 68.4% year-on-year growth, driven by demand in regulated markets, while the formulations segment grew by 41.1% due to enhanced market penetration and strategic partnerships. The company is strategically realigning its portfolio towards value-added exports and differentiated molecules to sustain growth and profitability.